Search…
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Search...
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Home
>
Latest
Lates News
21/08/2025
The main contract for the Shanghai Stock Exchange 50 Index Futures rose more than 1% intraday, now at 2870.0 points.
Latest
3 m ago
Jiangjian Group: Net profit in the first half of 2025 increased by 48.66% year-on-year.
3 m ago
Fokker: Net profit of 230 million yuan in the first half of 2025, a year-on-year decrease of 32.54%
3 m ago
Cui Dongshu: In recent years, China's automobile exports have performed excellently and are expected to maintain a small monthly growth trend in 2025.
3 m ago
Market news: Imran Khan, the detained Pakistani leader, will not be released.
4 m ago
According to each AI news, on August 21st, Cinda Securities released a research report granting a buy rating to Wanfu Biotechnology (300482.SZ). The main reasons for the rating include: 1) the recovery of the toxicology business growth, while infectious disease and chronic disease testing are under pressure; 2) short-term profitability pressure, with long-term growth driven by innovation. (Daily Economic News)
See all latest